{"site":"CJC-1295 Co","url":"https://cjc1295co.com","format":"evidence-manifest/v1","claim_count":53,"claims":[{"id":"CJC-001","text":"CJC-1295 has never been an FDA-approved drug: a Drugs@FDA search for products with active ingredient cjc-1295 returns no records.","source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/entity","https://cjc1295co.com/faq","https://cjc1295co.com/comparison","https://cjc1295co.com"]},{"id":"CJC-002","text":"FDA lists CJC-1295 on its compounding safety-risks page: compounded drugs containing it may pose immunogenicity risk for certain routes of administration and carry complexities for peptide-related impurities and API characterization.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/comparison","https://cjc1295co.com"]},{"id":"CJC-003","text":"FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-004","text":"FDA states that available clinical data on CJC-1295 are limited.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq"]},{"id":"CJC-005","text":"Compounded drugs are not FDA-approved; FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq"]},{"id":"CJC-006","text":"G33 disclosure string (rendered verbatim on homepage and monograph): CJC-1295 is not FDA approved. FDA has linked it to reports of serious adverse events (including increased heart rate), and it is sold only as a research chemical.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com","https://cjc1295co.com/monograph","https://cjc1295co.com/entity"]},{"id":"CJC-007","text":"The WADA 2026 Prohibited List names CJC-1295 explicitly under S2.2.4, growth hormone releasing factors: prohibited at all times for athletes.","source_url":"https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-008","text":"The only registered interventional trial of CJC-1295, a ConjuChem phase 2 study in HIV-associated visceral obesity started in December 2005, is recorded as TERMINATED with no results posted; its registry record was last updated October 16, 2006.","source_url":"https://clinicaltrials.gov/study/NCT00267527","grade":"registry","grade_label":"Registry record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com"]},{"id":"CJC-009","text":"As of August 14, 2026, ClinicalTrials.gov returns exactly one interventional study for CJC-1295 (the terminated phase 2); no active, recruiting, or completed efficacy trial exists in the registry.","source_url":"https://clinicaltrials.gov/api/v2/studies?query.term=CJC-1295&pageSize=20","grade":"absence-of-evidence","grade_label":"Absence of evidence","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq"]},{"id":"CJC-010","text":"FDA's substance registry (GSRS, UNII 62RC32V9N7) records CJC-1295 as a 30-residue amidated peptide with sequence YaDAIFTQSYRKVLAQLSARKLLQDILSRK, the lowercase a marking D-alanine at position 2 and a 30th residue lysine that carries the albumin-binding linker.","source_url":"https://precision.fda.gov/uniisearch/srs/unii/62RC32V9N7","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/comparison"]},{"id":"CJC-011","text":"PubChem records CJC-1295 as CID 91971820: molecular formula C165H269N47O46, molecular weight 3647.2 Da, CAS 446262-90-4, UNII 62RC32V9N7.","source_url":"https://pubchem.ncbi.nlm.nih.gov/compound/91971820","grade":"chemical-reference","grade_label":"Chemical reference","used_on":["https://cjc1295co.com/entity","https://cjc1295co.com/monograph"]},{"id":"CJC-012","text":"Sermorelin was formerly FDA-approved as Geref; FDA determined in 2013 that Geref was not withdrawn from sale for reasons of safety or effectiveness, and Drugs@FDA lists it as Discontinued.","source_url":"https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/comparison","https://cjc1295co.com/monograph"]},{"id":"CJC-013","text":"Sermorelin does not appear anywhere on FDA's compounding safety-risks page; CJC-1295 does. This is a checked absence: zero matches for sermorelin in the fetched page text.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","grade":"absence-of-evidence","grade_label":"Absence of evidence","used_on":["https://cjc1295co.com/comparison"]},{"id":"CJC-014","text":"Ipamorelin also appears on FDA's compounding safety-risks page, which cites a published study identifying serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","grade":"regulatory","grade_label":"Regulatory record","used_on":["https://cjc1295co.com/comparison","https://cjc1295co.com/faq"]},{"id":"CJC-015","text":"Tesamorelin (Egrifta SV) is the one GHRH analog with a current FDA approval, indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy.","source_url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224","grade":"fda-label","grade_label":"FDA label","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/decision_aid","https://cjc1295co.com/comparison"]},{"id":"CJC-020","text":"The core human evidence for CJC-1295 is two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, lasting 28 and 49 days (Teichman 2006).","source_url":"https://europepmc.org/article/MED/16352683","grade":"human-rct","grade_label":"Human RCT","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-021","text":"A single subcutaneous injection of CJC-1295 produced dose-dependent increases in mean plasma GH of 2- to 10-fold lasting 6 days or more.","source_url":"https://europepmc.org/article/MED/16352683","grade":"human-rct","grade_label":"Human RCT","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-022","text":"The same single injections raised mean plasma IGF-I 1.5- to 3-fold for 9 to 11 days.","source_url":"https://europepmc.org/article/MED/16352683","grade":"human-rct","grade_label":"Human RCT","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-023","text":"The estimated half-life of CJC-1295 (with DAC) in humans is 5.8 to 8.1 days.","source_url":"https://europepmc.org/article/MED/16352683","grade":"human-pk","grade_label":"Human PK","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/comparison","https://cjc1295co.com/tools","https://cjc1295co.com"]},{"id":"CJC-024","text":"After multiple weekly or biweekly doses, mean IGF-I remained above baseline for up to 28 days, with evidence of a cumulative effect.","source_url":"https://europepmc.org/article/MED/16352683","grade":"human-rct","grade_label":"Human RCT","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/tools"]},{"id":"CJC-025","text":"Within the 2006 trials themselves, no serious adverse reactions were reported, and the paper describes CJC-1295 as relatively well tolerated, particularly at 30 or 60 mcg/kg.","source_url":"https://europepmc.org/article/MED/16352683","grade":"human-rct","grade_label":"Human RCT","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com","https://cjc1295co.com/tools"]},{"id":"CJC-026","text":"The trials' main outcome measures were hormone concentrations (peak and area-under-curve GH and IGF-I) and pharmacokinetics; no body-composition, strength, sleep, recovery, or clinical outcome was a measured endpoint.","source_url":"https://europepmc.org/article/MED/16352683","grade":"human-rct","grade_label":"Human RCT","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com"]},{"id":"CJC-027","text":"Ionescu and Frohman studied GH pulsatility in healthy men aged 20 to 40 with overnight 12-hour blood sampling every 20 minutes, before and one week after a single injection of 60 or 90 mcg/kg CJC-1295.","source_url":"https://europepmc.org/article/MED/17018654","grade":"human-trial","grade_label":"Human trial","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/tools"]},{"id":"CJC-028","text":"One week after a single CJC-1295 dose, GH secretion remained pulsatile: the frequency and magnitude of GH secretory pulses were unaltered.","source_url":"https://europepmc.org/article/MED/17018654","grade":"human-trial","grade_label":"Human trial","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-029","text":"What changed was the floor, not the pulses: trough (basal) GH rose 7.5-fold (P<0.0001), lifting mean GH by 46% and IGF-I by 45%.","source_url":"https://europepmc.org/article/MED/17018654","grade":"human-trial","grade_label":"Human trial","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com","https://cjc1295co.com/tools"]},{"id":"CJC-030","text":"The 60 and 90 mcg/kg doses produced no significantly different responses, and the IGF-I increases did not correlate with any measured GH secretion parameter.","source_url":"https://europepmc.org/article/MED/17018654","grade":"human-trial","grade_label":"Human trial","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/tools"]},{"id":"CJC-031","text":"A proteomics study of 11 healthy young men, sampled before and one week after a CJC-1295 injection, found serum protein shifts: apolipoprotein A1 and transthyretin isoform spots decreased, while beta-hemoglobin and albumin-fragment spots increased.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/","grade":"human-uncontrolled","grade_label":"Uncontrolled human series","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-035","text":"CJC-1295 was identified at ConjuChem in 2005 as a tetrasubstituted form of hGRF(1-29) carrying an N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus.","source_url":"https://europepmc.org/article/MED/15817669","grade":"animal","grade_label":"Animal","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/comparison","https://cjc1295co.com/entity"]},{"id":"CJC-036","text":"The maleimide linker bioconjugates to the free thiol on Cys34 of serum albumin; in rats, a CJC-1295 immunoreactive species appeared on the albumin band within 15 minutes and remained beyond 24 hours.","source_url":"https://europepmc.org/article/MED/15817669","grade":"animal","grade_label":"Animal","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/tools"]},{"id":"CJC-037","text":"The albumin conjugates showed enhanced in vitro stability against dipeptidylpeptidase-IV while remaining bioactive in a GH secretion assay in cultured rat pituitary cells.","source_url":"https://europepmc.org/article/MED/15817669","grade":"in-vitro","grade_label":"In vitro","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-038","text":"In rats, CJC-1295 produced a 4-fold increase in GH area under the curve over 2 hours compared with unmodified hGRF(1-29) and was still present in plasma beyond 72 hours.","source_url":"https://europepmc.org/article/MED/15817669","grade":"animal-pk","grade_label":"Animal PK","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-039","text":"Native GHRH is cleaved in plasma at the 2-3 amino acid bond by dipeptidylpeptidase IV; a D-amino acid at position 1 or 2 blocks that hydrolysis, which is the mechanistic rationale for the D-Ala2 substitution in modified GRF(1-29) peptides.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC303858/","grade":"in-vitro","grade_label":"In vitro","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/comparison"]},{"id":"CJC-040","text":"In GHRH-knockout mice, 2 mcg of CJC-1295 daily for 5 weeks normalized body weight and length and increased pituitary GH mRNA with somatotroph proliferation on immunohistochemistry; every-48-hour and every-72-hour dosing was less effective.","source_url":"https://europepmc.org/article/MED/16822960","grade":"animal","grade_label":"Animal","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-041","text":"Compared with native GHRH, CJC-1295 carries four amino-acid substitutions that increase resistance to proteolytic degradation.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/comparison","https://cjc1295co.com/entity"]},{"id":"CJC-042","text":"The DAC modification enables binding to circulating albumin, markedly prolonging exposure and producing longer-lasting elevations of GH and IGF-1 in healthy adults.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-045","text":"CJC-1295 without DAC (Mod GRF 1-29) remains essentially uncharacterized in the peer-reviewed human literature: no controlled clinical studies have directly evaluated it in humans.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"absence-of-evidence","grade_label":"Absence of evidence","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/comparison","https://cjc1295co.com","https://cjc1295co.com/tools"]},{"id":"CJC-046","text":"Claims made for the no-DAC form (physiologic pulsatility, body-composition effects) derive largely from extrapolation from related compounds, primarily sermorelin, and from non-academic sources rather than direct clinical evidence.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/comparison"]},{"id":"CJC-047","text":"The closest measured human anchor for a short-acting modified GRF: adding D-Ala2 alone to GRF(1-29) extended its disappearance half-time from 4.3 to 6.7 minutes and cut metabolic clearance from 39.7 to 21 mL/kg per minute in normal men.","source_url":"https://europepmc.org/article/MED/7962295","grade":"human-pk","grade_label":"Human PK","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/comparison","https://cjc1295co.com/tools"]},{"id":"CJC-050","text":"In 2009 the Norwegian doping-control laboratory identified a police-submitted unknown pharmaceutical preparation as a 29-amino-acid C-terminally amidated peptide whose sequence is consistent with material marketed as CJC-1295; the authors note such peptides are manufactured illicitly and reach the public before entering or completing clinical trials.","source_url":"https://europepmc.org/article/MED/21204297","grade":"analytical","grade_label":"Analytical study","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq","https://cjc1295co.com/comparison"]},{"id":"CJC-051","text":"A 2016 netnography of 23 forum threads on female CJC-1295 use documented motives (weight loss, muscle enhancement, youthful skin, sleep, injury recovery) alongside users' own concerns about dose estimation, cycling, and long-term consequences.","source_url":"https://europepmc.org/article/MED/26771670","grade":"qualitative","grade_label":"Qualitative report","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-052","text":"A 2026 peer-reviewed review documents the gap between studied and self-administered dosing: trials used 30 or 60 mcg/kg subcutaneously two to three times weekly or biweekly, while bodybuilding forums describe 1 to 2 mg per week of the DAC form and 100 to 200 mcg one to two times daily of the no-DAC form, often combined with ipamorelin.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/tools","https://cjc1295co.com/faq","https://cjc1295co.com/comparison"]},{"id":"CJC-053","text":"A 2026 JBJS review classes GH-axis secretagogues including CJC-1295 as investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions.","source_url":"https://europepmc.org/article/MED/42160466","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-054","text":"A 2026 Sports Medicine review describes the unapproved-peptide gray market as operating largely outside regulatory oversight, with scarce rigorous human safety data and potential for serious harm to patients.","source_url":"https://europepmc.org/article/MED/41966639","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-055","text":"A 2026 critical review of peptide use in sport reports emerging class-level risk signals (cardiovascular strain, insulin resistance, dyslipidemia, psychiatric instability) and an unregulated supply chain in which products are often mislabeled or contaminated.","source_url":"https://europepmc.org/article/MED/41880199","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph"]},{"id":"CJC-058","text":"The popular CJC-1295 plus ipamorelin stack is, per a 2026 peer-reviewed review, largely driven by anecdotal rationale: controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy individuals remains limited.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/comparison","https://cjc1295co.com/faq","https://cjc1295co.com/monograph"]},{"id":"CJC-059","text":"Ipamorelin acts on a different receptor than CJC-1295: it is a selective ghrelin-receptor (GHRP-class) agonist that in animal studies released GH without significantly raising ACTH or cortisol, even at doses more than 200-fold its ED50.","source_url":"https://europepmc.org/article/MED/9849822","grade":"animal","grade_label":"Animal","used_on":["https://cjc1295co.com/comparison","https://cjc1295co.com/faq"]},{"id":"CJC-060","text":"The mechanistic rationale for pairing a GHRH analog with a ghrelin-receptor agonist has real acute-physiology roots: GHRP-6, the prototype of ipamorelin's class, showed enhanced GH secretion when combined with GHRH in human studies. That acute synergy has not been shown for the CJC-1295 plus ipamorelin pairing itself.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/comparison","https://cjc1295co.com/faq"]},{"id":"CJC-061","text":"No clinical trial of the CJC-1295 plus ipamorelin combination exists: the registry lists no combination study, and the 2026 review finds controlled clinical evidence for the stack limited.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"absence-of-evidence","grade_label":"Absence of evidence","used_on":["https://cjc1295co.com/comparison","https://cjc1295co.com/faq","https://cjc1295co.com/monograph"]},{"id":"CJC-065","text":"For scale on what raising the GH axis achieves in healthy people: pooled randomized trials of growth hormone itself in the healthy elderly found about 2.1 kg less fat and 2.1 kg more lean mass, no significant weight change, and significantly more soft tissue edema, arthralgia, carpal tunnel syndrome, and gynecomastia; the review concluded GH cannot be recommended as an antiaging therapy.","source_url":"https://europepmc.org/article/MED/17227934","grade":"meta-analysis","grade_label":"Meta-analysis","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq"]},{"id":"CJC-066","text":"The longest GHRH-analog trial in aging adults (16 weeks of nightly [Nle27]GHRH(1-29)) saw IGF-I rise within 2 weeks and then return toward baseline by week 16; skin thickness increased, lean mass rose in men only, sleep quality was unchanged, and the one adverse effect was transient hyperlipidemia.","source_url":"https://europepmc.org/article/MED/9141536","grade":"human-trial","grade_label":"Human trial","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq"]},{"id":"CJC-067","text":"The open safety question that matters most for a week-long GH bleed: the 2026 review advises that repeated or sustained elevation of IGF-1 should be considered a biologically plausible risk amplifier for cancer, particularly in people with prior malignancy, strong family history, or premalignant conditions.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq"]},{"id":"CJC-068","text":"Trial results transfer poorly to gray-market reality: controlled data came from pharmaceutical-grade compound at defined doses in defined populations, while off-label users self-administer products of uncertain identity and purity, at higher and more variable doses, frequently stacked, over timeframes exceeding the trials.","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13322892/","grade":"review","grade_label":"Review or guideline","used_on":["https://cjc1295co.com/monograph","https://cjc1295co.com/faq"]},{"id":"CJC-069","text":"Site self-counts used in the hero: 27 fetch-verified citations in the reference manifest (16 peer-reviewed, 10 government, 1 anti-doping authority), 14 species-labeled study-table rows of which 4 are human studies, and 0 completed human efficacy trials for body composition or any functional outcome.","source_url":"https://cjc1295co.com/monograph","grade":"internal-measurement","grade_label":"Internal measurement","used_on":["https://cjc1295co.com","https://cjc1295co.com/copy"]}]}